Catalyst Biosciences Inc (CBIO) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $3.50. Rodman & Renshaw advised their investors in a research report released on Jun 30, 2016.
In a different news, on Dec 18, 2015, Stephen A Hill (director) purchased 5,000 shares at $2.03 per share price. According to the SEC, on Dec 18, 2015, Fletcher Payne (CFO) purchased 10,000 shares at $2.00 per share price. On Dec 18, 2015, Nassim Usman (CEO) purchased 4,000 shares at $2.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Catalyst Bioscience Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis including the treatment of hemophilia and surgical bleeding and inflammation including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant CB 813d which has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition it has two other coagulation factors a Factor IX variant CB 2679d/ISU 304 which is in advanced preclinical development and a Factor Xa variant which is in the advanced lead stage of development. Its second area of focus is regulation of the complement cascade.